Big Pharma's emerging markets sales growth plunged to a new low last quarter. But within the group's overall average, some companies--such as…

The Attorney General in New York and some patients have filed suits against insurers that have balked at covering expensive hepatitis C drugs, while Medicaid…

Mylan is facing the prospect of investigations--as well as public criticism--following years of price increases on its big-selling EpiPen.

When one M&A door closes, many windows open. After Pfizer wrapped up a $14B Medivation buy Monday, investors bid up BioMarin, Incyte and more as likely…

Despite a renewed push by health officials to promote HPV vaccination, a new poll finds that only a minority of parents believe laws requiring the vaccines “…

The second-guessing has begun: Would Sanofi have had a shot at winning Medivation if it hadn’t gone hostile so quickly?

This year’s stock market hasn’t been easy for pharma. Unwelcome news has sent some drugmakers' shares tumbling--as much as 72%, in one notorious case.

Valeant CEO Joseph Papa has filled another link in the company's executive rank, hiring Zoetis and Warner Chilcott veteran Paul S. Herendeen, as chief…